Company Overview More
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company’s preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It is also developing APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer; and other pre-clinical development stage therapeutics focused on hematologic and solid tumors. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
CEO: White, Marvin L.
Market: NASDAQ
Futu Hot List
USHKCN
Trade HeatSearch HeatNews Heat
SymbolLatest Price% Chg

Loading...

Moomoo > Quotes > APVO Aptevo Therapeutics > Detailed Quotes

APVO Aptevo Therapeutics

13.070+1.120+9.37%
Close 11/26 16:56 ET
12.510-0.56-4.28%
Post Mkt Price 11/26 16:52 ET
High
14.100
Open
12.900
Turnover
97.20M
Low
11.250
Prev.Close
11.950
Volume
7.62M
Market Cap
64.02M
P/E(TTM)
Loss
52Wk High
51.750
Shares
4.90M
P/E
Loss
52Wk Low
6.380
H Mkt Cap
34.07M
Bid-Ask Ratio
50.00%
Historical High
88.900
H Shares
2.61M
Vol. Ratio
0.37
Historical Low
2.940
Dividend TTM
--
Div Yield TTM
--
P/B
8.78
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
292.13%
Amplitude
23.85%
Avg Price
12.762
Min Trading Unit
1
Float Market Cap
34.07M
Bid-Ask Ratio
50.00%
Historical High
88.900
Float
2.61M
Vol. Ratio
0.37
Historical Low
2.940
Dividend TTM
--
P/B
8.78
Dividend LFY
--
Turnover Ratio
292.13%
Amplitude
23.85%
Avg Price
12.762
Min Trading Unit
1
Price Forecast

Loading...

News